Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
Artielle Immunotherapeutics Announces Positive Results of Phase ! Multiple Sclerosis Trial
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.
Yield of emergent neuroimaging among children presenting with a first complex febrile seizure.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Laquinimod for multiple sclerosis.
Fingolimod-A sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes.
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Generic Midamor
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis.
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.

Pages